Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 346 AL 358

Omega-3 fatty acids for the treatment of dementia

Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A.

Cochrane Database Syst Rev. 2016 Apr 11;4(4):CD009002. doi: 10.1002/14651858.CD009002.pub3.

Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases

Hernando S, Gartziandia O, Herran E, Pedraz JL, Igartua M, Hernandez RM.

Nanomedicine (Lond). 2016 May;11(10):1267-85. doi: 10.2217/nnm-2016-0019. Epub 2016 Apr 14.

Cognitive interventions in Alzheimer's and Parkinson's diseases: emerging mechanisms and role of imaging

Vemuri P, Fields J, Peter J, Klöppel S.

Curr Opin Neurol. 2016 Aug;29(4):405-11. doi: 10.1097/WCO.0000000000000346.

A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease

McGhee DJ, Ritchie CW, Zajicek JP, Counsell CE.

BMC Neurol. 2016 Jun 16;16:92. doi: 10.1186/s12883-016-0606-3.

Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases

Parnetti L, Eusebi P, Lleó A.

Front Neurol Neurosci. 2016;39:117-23. doi: 10.1159/000445452. Epub 2016 Jul 26.

Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems

Cunha S, Amaral MH, Lobo JM, Silva AC.

Curr Med Chem. 2016;23(31):3618-3631. doi: 10.2174/0929867323666160824162401.

Endocannabinoid System in Neurological Disorders

Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM.

Recent Pat CNS Drug Discov. 2016;10(2):90-112. doi: 10.2174/1574889810999160719105433.

[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy]

Pupyshev AB, Korolenko TA, Tikhonova MA.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2016 Sep;66(5):515-540.

The rationale for deep brain stimulation in Alzheimer's disease

Mirzadeh Z, Bari A, Lozano AM.

J Neural Transm (Vienna). 2016 Jul;123(7):775-783. doi: 10.1007/s00702-015-1462-9. Epub 2015 Oct 6.

Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases

Shetty AK, Bates A.

Brain Res. 2016 May 1;1638(Pt A):74-87. doi: 10.1016/j.brainres.2015.09.019. Epub 2015 Sep 28.

Purinergic receptors as potential therapeutic targets in Alzheimer's disease

Woods LT, Ajit D, Camden JM, Erb L, Weisman GA.

Neuropharmacology. 2016 May;104:169-79. doi: 10.1016/j.neuropharm.2015.10.031. Epub 2015 Oct 28.

Bilateral deep brain stimulation of the fornix for Alzheimer's disease: surgical safety in the ADvance trial

Ponce FA, Asaad WF, Foote KD, Anderson WS, Rees Cosgrove G, Baltuch GH, Beasley K, Reymers DE, Oh ES, Targum SD, Smith GS, Lyketsos CG, Lozano AM; ADvance Research Group.

J Neurosurg. 2016 Jul;125(1):75-84. doi: 10.3171/2015.6.JNS15716. Epub 2015 Dec 18.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias